Syros Pharmaceuticals’ (SYRS) Hold Rating Reaffirmed at TD Cowen

TD Cowen reiterated their hold rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note published on Wednesday morning, Marketbeat Ratings reports.

Other equities research analysts have also issued reports about the company. StockNews.com lowered Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Piper Sandler reiterated an “overweight” rating and issued a $5.00 target price (down from $13.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Syros Pharmaceuticals in a research report on Friday, November 1st. Finally, JMP Securities lowered their price target on Syros Pharmaceuticals from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, Syros Pharmaceuticals presently has an average rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Stock Performance

Shares of SYRS opened at $0.26 on Wednesday. The firm has a market cap of $6.96 million, a price-to-earnings ratio of -0.09 and a beta of 1.59. The company’s fifty day moving average is $1.99 and its 200-day moving average is $3.75. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97. Syros Pharmaceuticals has a 12 month low of $0.25 and a 12 month high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same quarter last year, the company earned ($1.35) EPS. Equities analysts expect that Syros Pharmaceuticals will post -2.99 EPS for the current fiscal year.

Insider Activity at Syros Pharmaceuticals

In other news, CEO Conley Chee acquired 50,000 shares of Syros Pharmaceuticals stock in a transaction on Tuesday, September 10th. The stock was bought at an average price of $1.51 per share, for a total transaction of $75,500.00. Following the transaction, the chief executive officer now owns 72,504 shares of the company’s stock, valued at $109,481.04. The trade was a 222.18 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Jason Haas acquired 35,363 shares of Syros Pharmaceuticals stock in a transaction on Tuesday, September 10th. The stock was purchased at an average price of $1.55 per share, with a total value of $54,812.65. Following the transaction, the chief financial officer now directly owns 59,915 shares in the company, valued at approximately $92,868.25. This trade represents a 144.03 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 130,707 shares of company stock worth $206,491 in the last 90 days. 12.26% of the stock is owned by company insiders.

Institutional Trading of Syros Pharmaceuticals

A number of hedge funds have recently modified their holdings of SYRS. GSA Capital Partners LLP bought a new position in shares of Syros Pharmaceuticals during the 3rd quarter worth approximately $34,000. Virtu Financial LLC acquired a new stake in Syros Pharmaceuticals during the 1st quarter valued at $64,000. Acadian Asset Management LLC acquired a new stake in Syros Pharmaceuticals during the 1st quarter valued at $91,000. Certuity LLC acquired a new stake in Syros Pharmaceuticals during the 2nd quarter valued at $109,000. Finally, Kennedy Capital Management LLC acquired a new stake in Syros Pharmaceuticals during the 1st quarter valued at $2,166,000. Institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.